Los Juegos Mejorados: pérdidas de $60 millones.

I traveled to Las Vegas in May to witness the Enhanced Games—an unprecedented sports event allowing athletes to use performance-enhancing drugs typically banned in professional sports. Dubbed the “steroid Olympics,” this event was orchestrated by a telehealth firm, underpinned by influential figures such as Peter Thiel, and staffed by veterans from the crypto, AI, and biotech domains.

The event, however, turned out to be anticlimactic. Marketed as a revolutionary transformation in organized sports, it fell short of expectations, yielding just one world record, which occurred in swimming—a domain known for frequent record-breaking.

Alongside being a competitive disappointment, the games proved to be a financial misstep. The Enhanced Group, responsible for hosting the games, reported a staggering net loss of nearly $62 million. This loss significantly stemmed from the games, reflecting a broader commercial failure.

Founded only in 2023, Enhanced Group had celebrated a successful IPO at a valuation of $1.2 billion and primarily sold personalized health treatments through a digital platform. However, recent earnings indicated that its revenue of $17.7 million in the last quarter was heavily reliant on sponsorships related to the games rather than its foundational telehealth services. The scant details about the performance of its core business raise doubts about previous claims regarding the games being an annual event, as sustaining such a loss poses a significant challenge.

In a potential pivot, Enhanced has introduced a new online series, Enhanced Breakers, aimed at maintaining audience engagement and sponsor interest while operating at a fraction of the cost of a full games event.

Despite Enhanced’s struggles, the surrounding industry is flourishing. The peptide market is experiencing substantial growth, spurred by a recent decision from the Food and Drug Administration under the Trump administration to reclassify various substances long in regulatory limbo. While this move has not yet opened the floodgates for widespread distribution, it signals governmental interest in lessening regulations.

Moreover, the oversight from the U.S. Department of Health and Human Services rests with Robert F. Kennedy Jr. His unconventional health views, while criticized by professionals, have not impeded the industry’s progress.

In Silicon Valley, a thriving hub for peptide startups, companies are sprouting, capitalizing on trends in biohacking and health supplements. Noteworthy entities like Superpower and Noho Labs are gaining traction, but the rapid growth of the sector often outpaces regulatory frameworks, leaving state authorities grappling to keep up with emerging trends.

Gracias por leer Columna Digital, puedes seguirnos en Facebook, Twitter, Instagram o visitar nuestra página oficial. No olvides comentar sobre este articulo directamente en la parte inferior de esta página, tu comentario es muy importante para nuestra área de redacción y nuestros lectores.